208 related articles for article (PubMed ID: 30972293)
1. Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.
Fumarola C; Bozza N; Castelli R; Ferlenghi F; Marseglia G; Lodola A; Bonelli M; La Monica S; Cretella D; Alfieri R; Minari R; Galetti M; Tiseo M; Ardizzoni A; Mor M; Petronini PG
Front Oncol; 2019; 9():179. PubMed ID: 30972293
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.
Fumarola C; Cretella D; La Monica S; Bonelli MA; Alfieri R; Caffarra C; Quaini F; Madeddu D; Falco A; Cavazzoni A; Digiacomo G; Mazzaschi G; Vivo V; Barocelli E; Tiseo M; Petronini PG; Ardizzoni A
Oncotarget; 2017 Nov; 8(54):91841-91859. PubMed ID: 29190880
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Primary Drug Resistance in
Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
[No Abstract] [Full Text] [Related]
4. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
5. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
6. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
Chi F; Griffiths JI; Nath A; Bild AH
Breast Cancer Res; 2024 Mar; 26(1):54. PubMed ID: 38553760
[TBL] [Abstract][Full Text] [Related]
8. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.
Datta J; Damodaran S; Parks H; Ocrainiciuc C; Miya J; Yu L; Gardner EP; Samorodnitsky E; Wing MR; Bhatt D; Hays J; Reeser JW; Roychowdhury S
Mol Cancer Ther; 2017 Apr; 16(4):614-624. PubMed ID: 28255027
[TBL] [Abstract][Full Text] [Related]
9. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.
Kim SM; Kim H; Yun MR; Kang HN; Pyo KH; Park HJ; Lee JM; Choi HM; Ellinghaus P; Ocker M; Paik S; Kim HR; Cho BC
Oncogenesis; 2016 Jul; 5(7):e241. PubMed ID: 27429073
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
Addeo A; Rothschild SI; Holer L; Schneider M; Waibel C; Haefliger S; Mark M; Fernandez E; Mach N; Mauti L; Jermann PM; Alborelli I; Calgua B; Savic-Prince S; Joerger M; Früh M
Lung Cancer; 2022 Oct; 172():154-159. PubMed ID: 36099710
[TBL] [Abstract][Full Text] [Related]
11. Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis.
Sahores A; May M; Sequeira GR; Fuentes C; Jacobsen B; Lanari C; Lamb CA
Curr Cancer Drug Targets; 2018; 18(10):979-987. PubMed ID: 29237381
[TBL] [Abstract][Full Text] [Related]
12. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
Golfmann K; Meder L; Koker M; Volz C; Borchmann S; Tharun L; Dietlein F; Malchers F; Florin A; Büttner R; Rosen N; Rodrik-Outmezguine V; Hallek M; Ullrich RT
Oncogene; 2018 Oct; 37(42):5682-5693. PubMed ID: 29970903
[TBL] [Abstract][Full Text] [Related]
14. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
[TBL] [Abstract][Full Text] [Related]
15. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
Botrus G; Raman P; Oliver T; Bekaii-Saab T
Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
[TBL] [Abstract][Full Text] [Related]
16. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
[TBL] [Abstract][Full Text] [Related]
17. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
[TBL] [Abstract][Full Text] [Related]
18. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.
Wang Y; Li L; Fan J; Dai Y; Jiang A; Geng M; Ai J; Duan W
J Med Chem; 2018 Oct; 61(20):9085-9104. PubMed ID: 29522671
[TBL] [Abstract][Full Text] [Related]
20. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
Cowell JK; Qin H; Hu T; Wu Q; Bhole A; Ren M
Int J Cancer; 2017 Nov; 141(9):1822-1829. PubMed ID: 28646488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
